Surrozen, Inc./DE Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Surrozen, Inc./DE (SRZN) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $15.80 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-23
- Surrozen, Inc./DE valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $15.80M.
- Surrozen, Inc./DE valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was -$2.10M, a 124.42% decline from fiscal 2023.
- Surrozen, Inc./DE valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $8.60M, a 11.34% decline from fiscal 2022.
- Surrozen, Inc./DE valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $9.70M, a 0.00% change from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $15.80M 10-K · filed 2026-03-23 |
| 2024-12-31 | -$2.10M 10-K · filed 2026-03-23 |
| 2023-12-31 | $8.60M 10-K · filed 2025-03-31 |
| 2022-12-31 | $9.70M 10-K · filed 2024-04-10 |
| 2021-12-31 | $9.70M 10-K · filed 2023-03-31 |
| 2020-12-31 | $9.60M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |